

UPLIZNA (INEBILIZUMAB) INFUSION ORDERS

P: 877.365.5566 | **F:** 855.889.2946

,, ,,	aretori company					
PATIENT I	NFORMATIO	N: Fax complet	ted form, insurar	ce information, and	clinical documer	ntation to 855.889.2946
Patient Name	:			DOB:	Phone: _	
Patient Statu	s: □ New to Th	erapy 🗆 Continuin	g Therapy	Next Treatment	Date:	
MEDICAL I	NFORMATIO	N				
	☐ IgG4 related	is optica spectrun disease (ICD-10	Code: D89.8	34)		_)
Patient Weig	ght: lbs	s. Allergies:				
THERAPY	ORDER					
	osing: 300mg	IV followed by 30 months from the	00mg IV 2 w	eeks later, ther		
Protocol Pre	e-Medication (Orders: Solu-Medr to be give		•	-	ylenol 650mg PO ontraindications)
Other orders	S:					
Lab Orders:			L	ab Frequency:		
Required lab	os to be drawn	by: 🗌 Infusion C	Center 🗌 R	eferring Provid	er	
Epinephrine>30kgDiphenhyde0.9% NS 10	ramine: Administe 00mL bolus per p	nt weight) 0.3mg or compounde r 25-50mg orally OR IV	V			
PROVIDER	INFORMATI	ON				
By signing this form ar agent in dealing with r Provider Nam Provider NPI:	nd utilizing our services, you nedical and prescription in e:	ou are authorizing <i>Paragon Healt</i> surance companies, and to select some select select some select some select some select some select select select some select	et the preferred site of Signature: Fax:	care for the patient. Cont	tact Person: _	
		State:	_ View	our locations hei	re: 0 4 4	

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





COMPREHENSIVE SUPPORT FOR UPLIZNA THERAPY

PATIENT INFORMATION:
Patient Name: DOB:
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
☐ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)
☐ Include patient demographic information and insurance information
☐ Include patient's current medication list
\square Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
For NMOSD (required), please answer:
☐ Has the patient had a documented contraindication/intolerance or failed trial of rituximab, azathioprine, or mycophenolate mofetil? ☐ Yes ☐ No
 □ Does the patient have a history of at least one relapse (acute attack from neuromyelitis spectrum disorder) in the last 12 months, or two relapses in the last 2 years? □ Yes □ No
☐ Expanded Disability Status Score (EDSS):
For IgG4-RD (required), please answer:
☐ ACR/EULAR IgG4-RD Classification Criteria Score:
 ☐ Has the patient had a documented contraindication/intolerance or failed trial of rituximab, steroid, or immunosuppressant? ☐ Yes ☐ No If yes, please indicate which drug(s):
☐ Include labs (i.e., IgG4) and/or test results to support diagnosis
☐ Other medical necessity:
REQUIRED PRE-SCREENING
☐ TB screening test completed within 12 months - attach results☐ Positive☐ Negative
☐ Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis B core antibody total (not IgM) - attach results
☐ Positive ☐ Negative
☐ Serum immunoglobulins - attach results
☐ AQP4 positive antibody lab (NMOSD diagnosis) - attach results

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance